- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.12. | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11. | bioAffinity Technologies: EPS verfehlt Schätzungen um 4,65 $ - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| 14.11. | bioAffinity Technologies GAAP EPS of -$4.74, revenue of $1.45M | 1 | Seeking Alpha | ||
| 14.11. | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | bioAffinity reports 111% increase in lung cancer test volume | 3 | Investing.com | ||
| 05.11. | bioAffinity Technologies, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.10. | bioAffinity receives Australian patent acceptance for lung disease test | 2 | Investing.com | ||
| BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 28.10. | bioAffinity erhält australische Patentzusage für Test zur Lungengesundheit | 1 | Investing.com Deutsch | ||
| 28.10. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains? | 8 | Benzinga.com | ||
| 16.10. | bioAffinity stock soars after receiving patent allowance for AI lung cancer test | 1 | Investing.com | ||
| 16.10. | Patent für KI-Lungenkrebstest beflügelt bioAffinity-Aktie | - | Investing.com Deutsch | ||
| 15.10. | bioAffinity Technologies, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 15.10. | Biotechnology company bioAffinity regains compliance with Nasdaq's continued listing rules | 4 | Seeking Alpha | ||
| 15.10. | bioAffinity Technologies erfüllt wieder Nasdaq-Anforderungen | 2 | Investing.com Deutsch | ||
| 09.10. | bioAffinity Technologies schließt registrierte Direktplatzierung über 1,8 Millionen US-Dollar ab | 1 | Investing.com Deutsch | ||
| 09.10. | bioAffinity Technologies closes $1.8 million registered direct offering | 1 | Investing.com | ||
| 08.10. | bioAffinity Technologies raises $1.8 million in registered direct offering | 1 | Investing.com | ||
| 08.10. | bioAffinity Technologies launches $1.8M direct financing | 1 | Seeking Alpha | ||
| 08.10. | bioAffinity Technologies nimmt 1,8 Millionen US-Dollar durch Direktangebot ein | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,401 | +1,52 % | BioNxt treibt "Melt in Your Mouth"-Cladribin-Formulierung voran, um die Behandlung von MS-Patienten mit Dysphagie zu verbessern | VANCOUVER, BC / ACCESS Newswire / 9. Dezember 2025 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT) meldet Fortschritte bei der Entwicklung einer neuartigen... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,490 | -1,19 % | Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates | Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,210 | -11,33 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,940 | +1,08 % | Onco-Innovations Limited: Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care | VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce, further to its... ► Artikel lesen | |
| NEOVACS | 0,011 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 18.07.2025 | The following instruments on XETRA do have their first trading 18.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.07.2025
Aktien
1 KYG7388C1033 Qunabox Group Ltd.
2... ► Artikel lesen | |
| CYBIN | 5,750 | +0,88 % | Cybin Inc.: Cybin to Participate in the Jefferies Global Healthcare Conference in London | Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary... ► Artikel lesen | |
| BIOLINERX | 2,670 | +6,80 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| BIOARCTIC | 29,660 | -0,07 % | BioArctic: Leqembi included in China's commercial insurance innovative drug list | STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab), has been included in the "Commercial Insurance... ► Artikel lesen | |
| NUCANA | 3,620 | 0,00 % | NuCana plc: NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma | Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier FindingsEDINBURGH, United Kingdom, Dec. 10, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| GENSIGHT BIOLOGICS | 0,082 | -7,74 % | GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ REVISE Dose-Ranging Study in France | French medicines agency ANSM and Ethics Committee authorize the dose-ranging study investigating two doses of candidate product for the treatment of ND4-LHON.
Approval of the study protocol... ► Artikel lesen | |
| IMMUNOME | 22,640 | 0,00 % | Why Immunome Stock Surged Today | ||
| PEPGEN | 5,465 | 0,00 % | PepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society | PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 76,81 | -0,35 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| RECURSION PHARMACEUTICALS | 4,200 | 0,00 % | Why Recursion Pharamaceuticals Topped the Market Today | ||
| ADMA BIOLOGICS | 19,730 | -0,25 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
Das Unternehmen BIOAFFINITY TECHNOLOGIES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,65 % bei einem Aktienkurs von 1,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.